Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Oct 26, 2023; 11(30): 7432-7439
Published online Oct 26, 2023. doi: 10.12998/wjcc.v11.i30.7432
Diffuse large B-cell lymphoma successfully treated with amplified natural killer therapy alone: A case report
Kenjiro Nagai, Syo Nagai, Yuji Okubo, Keisuke Teshigawara
Kenjiro Nagai, Syo Nagai, Department of Internal Medicine, Medical Corporation Ebino Centro Clinic, Ebino 889-4304, Japan
Yuji Okubo, Keisuke Teshigawara, Department of Internal Medicine, Higashinotoin Clinic, Kyoto 604-8175, Japan
Author contributions: Nagai K and Nagai S contributed to manuscript writing and editing, and data collection; Okubo Y contributed to data analysis; Teshigawara K contributed to conceptualization and supervision; all authors have read and approved the final manuscript.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kenjiro Nagai, MD, Chief Doctor, Internal Medicine, Medical Corporation Ebino Centro Clinic, 1007-4 Uwae, Ebino City, Miyazaki Prefecture, Ebino 889-4304, Japan. ken701n427@gmail.com
Received: July 21, 2023
Peer-review started: July 21, 2023
First decision: September 13, 2023
Revised: September 26, 2023
Accepted: October 8, 2023
Article in press: October 8, 2023
Published online: October 26, 2023
Processing time: 95 Days and 19.9 Hours
Core Tip

Core Tip: The current patient was programmed death ligand 1 (PD-L1) positive, and the treatment was highly effective. Accordingly, amplified natural killer (ANK) therapy could be employed as a first-line treatment for malignant lymphoma based on the therapeutic efficacy and minimal side effects. Moreover, the PD-L1 positivity rate may serve as a biomarker for predicting the efficacy of ANK therapy.